A phase 3 study evaluating mupadolimab (CPI-006), an investigational, humanized anti-CD73 antibody monoclonal antibody, for the treatment of COVID-19 has been discontinued.
The randomized, double-blind, placebo-controlled study (ClinicalTrials.gov Identifier: NCT04734873) was evaluating the efficacy and safety of mupadolimab in mild to moderately symptomatic hospitalized COVID-19 patients. The decision to halt the study was made due to positive trends demonstrated by COVID-19 vaccines in lowering serious infection and hospitalizations. The study was not discontinued due to any efficacy or safety concerns related to mupadolimab.
The Company will continue to investigate mupadolimab for the treatment of advanced, human papillomavirus positive head and neck cancer. “We are prioritizing resources on mupadolimab in oncology and intensifying our efforts in our cancer programs,” said Richard A. Miller, MD, co-founder, President and CEO of Corvus.
Corvus Pharmaceuticals discontinues phase 3 study of mupadolimab (anti-CD73) for COVID-19 due to vaccine effectiveness in reducing hospitalizations. News release. Corvus Pharmaceuticals, Inc. Accessed July 16, 2021. https://www.globenewswire.com/news-release/2021/07/15/2263919/0/en/Corvus-Pharmaceuticals-Discontinues-Phase-3-Study-of-Mupadolimab-Anti-CD73-for-COVID-19-Due-to-Vaccine-Effectiveness-in-Reducing-Hospitalizations.html.